Vitamin A Deficiency – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Vitamin A Deficiency Market Outlook

Thelansis’s “Vitamin A Deficiency Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Vitamin A Deficiency treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Vitamin A Deficiency Overview

Vitamin A is a lipid-soluble micronutrient that plays a vital role in cellular development, metabolism, immune function, vision, and reproductive processes. Insufficient intake or absorption of vitamin A can lead to a deficiency, impairing important physiological functions. Vitamin A deficiency (VAD) is a widespread health concern affecting young children and is associated with significant morbidity and mortality. According to the Institute of Medicine, the recommended dietary allowance (RDA) of vitamin A for healthy adults is 700 micrograms/day for women and 900 micrograms/day for men. Children, pregnant women, and lactating women have different RDAs, which are 300 to 900, 770, and 1300 micrograms/day, respectively. Ocular symptoms related to vitamin A deficiency have been observed to occur when blood concentrations are lower than 10 micrograms/dL. Inadequate nutrition compounded by chronic inflammation resulting from regular gastrointestinal (GI) infections is the primary cause of vitamin A deficiency. This situation often leads to multiple micronutrient deficiencies. Vitamin A is crucial for regenerating visual pigments, maintaining mucosal membranes, and proper immune function. Insufficient vitamin A levels can cause night blindness due to impaired regeneration of visual pigments in retinal rods. If the deficiency persists, the retinal rods will degenerate, leading to a condition called xerophthalmia, which can result in permanent blindness. Insufficient vitamin A also leads to dryness and breakdown of the mucosal membranes in the intestines and lungs, along with compromised immune function, resulting in frequent infections and anemia caused by chronic inflammation. The recommended treatment for vitamin A deficiency is vitamin A supplementation. The prognosis of vitamin A deficiency depends on the severity of the disease when treatment is initiated. Severe vitamin A deficiency may lead to irreversible vision loss or blindness, heightened susceptibility to infections, and impaired immune function, significantly increasing mortality rates.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Vitamin A Deficiency – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034